Transport of thalidomide by the human intestinal caco-2 monolayers (Q40398700)

20 September 2017

Transport of thalidomide by the human intestinal caco-2 monolayers (English)

1 reference

20 September 2017

0 references

1 reference

Shufeng Zhou

1

1 reference

20 September 2017

Yan Li

2

1 reference

20 September 2017

Phillip Kestell

3

1 reference

20 September 2017

Peter Schafer

4

1 reference

20 September 2017

Eli Chan

5

1 reference

20 September 2017

James W Paxton

6

1 reference

20 September 2017

1 January 2005

1 reference

European Journal of Drug Metabolism and Pharmacokinetics

20 September 2017

1 reference

20 September 2017

30

1 reference

20 September 2017

1-2

1 reference

20 September 2017

49-61

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03226408

20 September 2017

0 references

cites work

Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Caco-2 monolayers in experimental and theoretical predictions of drug transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Molecular biology and regulation of nucleoside and nucleobase transporter proteins in eukaryotes and prokaryotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Clinical pharmacology of thalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Hydroxylated metabolites of thalidomide: formation in-vitro and in-vivo in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Phase II trial of thalidomide in renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Sodium dependence of nitrofurantoin active transport across mammary epithelia and effects of dipyridamole, nucleosides, and nucleobases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

A double-blind study of the sedative effects of the thalidomide enantiomers in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Thalidomide stimulates splenic IgM antibody response and cytotoxic T lymphocyte subpopulation numbers in female B6C3F1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Efficacy of a low dose of thalidomide in advanced multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Analgesic effect of thalidomide on inflammatory pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Thalidomide in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Measurement of protein using bicinchoninic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Mechanism of action in thalidomide teratogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Clinical pharmacokinetics of thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03226408

Pharmacokinetics of thalidomide in an elderly prostate cancer population

21 January 2018

1 reference

12 December 2020

Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers.

1 reference

12 December 2020

Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy

1 reference

12 December 2020

High-performance liquid chromatographic assay of plasma thalidomide: stabilization of specimens and determination of a tentative therapeutic range for chronic graft-versus-host disease

1 reference

12 December 2020

Transport characteristics of diphenhydramine in human intestinal epithelial Caco-2 cells: contribution of pH-dependent transport system.

1 reference

12 December 2020

The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum Leprosum

1 reference

12 December 2020

Thalidomide metabolism by the CYP2C subfamily.

1 reference

12 December 2020

Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients

1 reference

12 December 2020

Thalidomide and its analogues inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2.

1 reference

12 December 2020

Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions

1 reference

12 December 2020

Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist

1 reference

12 December 2020

Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump

1 reference

12 December 2020

Thalidomide in multiple myeloma

1 reference

12 December 2020

Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients

1 reference

12 December 2020

The transport of a reversible proton pump antagonist, 5, 6-dimethyl-2-(4-Fluorophenylamino)-4-(1-methyl-1,2,3, 4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across caco-2 cell monolayers

1 reference

12 December 2020

Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells.

1 reference

12 December 2020

Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cell.

1 reference

12 December 2020

Cellular uptake of dietary flavonoid quercetin 4'-beta-glucoside by sodium-dependent glucose transporter SGLT1

1 reference

12 December 2020

Pharmacological properties of thalidomide (alpha-phthalimido glutarimide), a new sedative hypnotic drug

1 reference

12 December 2020

Thalidomide treatment for chronic graft-versus-host disease

1 reference

12 December 2020

A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model

1 reference

12 December 2020

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

1 reference

12 December 2020

Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus

1 reference

12 December 2020

Thalidomide metabolites in mice and patients with multiple myeloma

1 reference

12 December 2020

Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450

1 reference

12 December 2020

Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers

1 reference

12 December 2020

Metabolism of L-alpha-methyldopa in cultured human intestinal epithelial (Caco-2) cell monolayers. Comparison with metabolism in vivo.

1 reference

12 December 2020

Stability of thalidomide in human plasma

1 reference

12 December 2020

Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans

1 reference

12 December 2020

Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid

1 reference

12 December 2020

The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve

1 reference

12 December 2020

The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution

1 reference

12 December 2020

Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin

1 reference

12 December 2020

Hepatic canalicular membrane 5: Expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03226408

1 reference

Dimensions Publication ID

20 September 2017

0 references

1 reference